Literature DB >> 6140291

Susceptibility testing of Entamoeba histolytica.

J R Cedeño, D J Krogstad.   

Abstract

The growth of Entamoeba histolytica in microtiter plates in vitro in a variety of environments with reduced oxygen tensions is reported. With 3% O2, 3% CO2, and 94% N2, the parasite growth in microtiter plates was identical to that in screw-capped culture tubes, as measured by [3H]thymidine incorporation and by quantitative parasite counts. There were no significant differences between the drug concentrations necessary to inhibit parasite growth by 50% based on [3H]thymidine incorporation vs those defined by quantitative parasite counts for the 15 antimicrobial agents tested (including seven drugs used for the treatment of amebiasis). This technique provides a reproducible method to quantitate the activity of potential antiamebic agents in vitro. The isotopic method should be of particular value in defining the metabolism of the parasite and effects of antimicrobial agents on it, whereas the morphologic method may be more valuable for workers with limited resources available to them.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140291     DOI: 10.1093/infdis/148.6.1090

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  In vitro activity of azithromycin and dirithromycin against axenic Entamoeba histolytica.

Authors:  S Ranque; B Molet; D Christmann; E Candolfi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

2.  Use of microdilution to assess in vitro antiamoebic activities of Brucea javanica fruits, Simarouba amara stem, and a number of quassinoids.

Authors:  C W Wright; M J O'Neill; J D Phillipson; D C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

3.  In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.

Authors:  J I Ravdin; J Skilogiannis
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 4.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

5.  Characterization of the recombination activities of the Entamoeba histolytica Rad51 recombinase.

Authors:  Andrew A Kelso; Steven D Goodson; Suchitra Chavan; Amanda F Say; Audrey Turchick; Deepti Sharma; LeAnna L Ledford; Erin Ratterman; Kristin Leskoske; Ada V King; Christopher C Attaway; Yura Bandera; Stephen H Foulger; Alexander V Mazin; Lesly A Temesvari; Michael G Sehorn
Journal:  Mol Biochem Parasitol       Date:  2016-09-24       Impact factor: 1.759

6.  Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers.

Authors:  J C Samuelson; A Burke; J M Courval
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Specific labeling of cysteine proteinases in pathogenic and nonpathogenic Entamoeba histolytica.

Authors:  F de Meester; E Shaw; H Scholze; T Stolarsky; D Mirelman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  In vitro activity of pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis using radiolabelled thymidine incorporation and an SYBR Green I-based fluorescence assay.

Authors:  Autumn S Downey; Thaddeus K Graczyk; David J Sullivan
Journal:  J Antimicrob Chemother       Date:  2009-08-18       Impact factor: 5.790

9.  Entamoeba histolytica Dmc1 Catalyzes Homologous DNA Pairing and Strand Exchange That Is Stimulated by Calcium and Hop2-Mnd1.

Authors:  Andrew A Kelso; Amanda F Say; Deepti Sharma; LeAnna L Ledford; Audrey Turchick; Christopher A Saski; Ada V King; Christopher C Attaway; Lesly A Temesvari; Michael G Sehorn
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

10.  Use of bacterially expressed dsRNA to downregulate Entamoeba histolytica gene expression.

Authors:  Carlos F Solis; Julien Santi-Rocca; Doranda Perdomo; Christian Weber; Nancy Guillén
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.